Winklevoss Entities Acquire Significant Stake in Leap Therapeutics

Winklevoss Capital Fund, LLC, Winklevoss Treasury Investments, LLC, Winklevoss Capital Management, LLC, Tyler Winklevoss, and Cameron Winklevoss (collectively, the 'Reporting Persons') have filed a Schedule 13D indicating their acquisition of a significant stake in Leap Therapeutics, Inc. The Reporting Persons now beneficially own approximately 19.99% of Leap Therapeutics' common stock, including shares issuable upon the exercise of warrants. The shares were acquired through a private placement transaction where Leap Therapeutics issued shares and warrants to accredited investors, including WTI. The Reporting Persons intend to nominate two directors to Leap Therapeutics' board and may engage in various investment activities, including purchasing additional shares, disposing of shares, or engaging in hedging transactions. The filing also includes details of the securities purchase agreement, lead investor agreement, and registration rights agreement.